

## Asthma Indicators for LHIN 6: Mississauga Halton

Indicator	Asthma Indicators for LHIN 6: Mississauga Halton																						
	1996	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017*	2018*
1. PFT used for diagnosis (% of incident asthma)†	54.7	55.5	50.9	48.5	46.9	48.5	48.2	47.0	47.5	48.1	50.6	51.9	50.0	49.7	51.8	49.9	48.1	46.8	47.9	51.1	52.0	54.6	56.5
2. PFT used for monitoring (% of prevalent asthma)†	16.8	15.6	15.4	13.1	11.0	10.3	9.2	8.7	8.2	7.9	8.1	8.0	8.0	7.4	7.3	7.1	6.8	6.3	6.2	6.2	6.4	6.4	6.7
3. ≥1 ICS prescription (% of active asthma prevalence)‡	56.6	54.6	53.2	51.8	51.0	50.6	49.2	47.2	48.1	47.6	46.5	46.5	46.8	45.9	46.4	48.6	48.4	48.7	48.0	48.1	46.8	44.0	41.2
4. ≥1 β2-agonist prescription (% of active asthma prevalence)‡	57.8	55.6	53.3	51.4	50.5	48.1	45.2	42.7	41.4	39.5	37.2	37.4	35.7	34.5	34.3	35.3	34.3	33.3	30.6	22.1	22.4	20.9	21.4
5. ≥1 asthma ED visit (% of prevalent asthma)	4.7	3.8	3.5	3.0	2.8	2.4	2.3	1.7	1.6	1.6	1.5	1.3	1.2	1.1	1.0	1.0	0.8	0.8	0.8	0.8	0.7	0.7	0.7
6. ≥1 asthma physician office visit (% of prevalent asthma)	39.2	35.0	32.1	30.9	27.7	26.5	23.8	22.1	21.4	20.9	20.0	19.4	18.8	17.5	17.7	16.8	15.9	15.4	15.3	15.3	14.1	13.7	13.5
7. β2-agonist use (% of active asthma prevalence)‡																							
≤4 canisters	47.7	49.6	51.7	52.8	53.3	54.8	56.0	57.0	57.9	61.3	62.1	63.1	65.6	66.7	66.4	67.8	68.4	70.1	71.6	70.7	72.3	72.0	72.0
5-12	30.8	31.2	30.1	28.8	29.6	29.0	28.7	29.0	29.4	28.0	27.7	27.7	26.2	25.5	26.3	25.5	26.1	24.2	23.0	24.2	23.4	23.2	23.1
13-20	14.0	12.0	11.3	11.3	10.9	10.0	9.9	8.8	8.1	7.2	6.8	6.2	6.3	5.7	5.5	5.2	4.3	4.5	4.2	3.9	3.2	3.9	3.8
>20	7.5	7.1	7.0	7.2	6.2	6.3	5.5	5.2	4.6	3.4	3.4	3.0	2.0	2.1	1.7	1.5	1.2	1.2	1.2	1.2	1.0	1.0	1.0

\*Reporting period is from April 1996 to March 2019. Data for 2017 and 2018 may be incomplete due to the 2-year algorithm to identify asthma, and numbers are subject to change.

PFT = pulmonary function test; ICS = inhaled corticosteroid; ED = emergency department

†PFT data refers only to those aged 7 and above.

‡Drug use data refers only to those aged 66 and above.

Notes: Active asthma cases are people who had at least one asthma claim during the year.

Asthma prevalence without whole year OHIP coverage were excluded.

People with missing LHIN or rurality were excluded.

OHIP data was up to December 2019 when the tables were created.

For asthma incidence from July 2017 to Mar 2019, PFT data for 2.5-year post asthma incidence are not completed since the data were only up to Dec. 2019 at the time when the tables were create

### Asthma indicators: detailed description:

1. Percent of asthma incidence aged 7 and above with a pulmonary function test in one year prior to or two and half years after incidence date
2. Percent of active asthma prevalence aged 7 and above with a pulmonary function test in one year prior to the date of first asthma health service use in the year
3. Percent of active asthma prevalence aged 66 and above with at least one prescription of inhaled corticosteroids in one year prior to the date of first asthma health service use in the year
4. Percent of active asthma prevalence aged 66 and above with at least one prescription of short acting B2-agonist in one year prior to the date of first asthma health service use in the year
5. Percent of asthma prevalence with at least one ED visit in one year prior to the date of first asthma health service use in the year
6. Percentage of asthma prevalence with at least one physician office visit in one year prior to the date of first asthma health service use in the year
7. Distribution of the four categories of β2-agonist use for active asthma prevalence aged 65+

Source: This table uses statistics reported by the Ontario Asthma Surveillance Information System (OASIS) and data provided by ICES, Ontario.